Managing oral anticoagulation therapy: Improving clinical outcomes. A review

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 6, 2008, Pages 581-590

  Ryan, F ^a   Byrne, S ^a   O'Shea, S ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Oral anticoagulation therapy; Practice improvement; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DECISION SUPPORT SYSTEM; DRUG MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; OUTCOME ASSESSMENT; PATIENT SAFETY; PHARMACOGENETICS; PRIMARY MEDICAL CARE; REVIEW; THROMBOSIS;

ADMINISTRATION, ORAL; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; DECISION MAKING, COMPUTER-ASSISTED; DRUG MONITORING; HUMANS; PHARMACOGENETICS; TREATMENT OUTCOME;

EID: 55949105522     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00959.x     Document Type: Review

References (69)

1. Baglin TP, Keeling DM, Watson HG (2005) Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. British Journal of Haematology, 132, 277 285.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. The Journal of the American Medical Association, 285, 2370 2375.
3. Beyth R, Antani M, Covinsky KE, Miller DG, Chren MM, Quinn LM, Landefeld CS (1996) Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? Journal of General Internal Medicine, 11, 721 728.
4. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S (2004) Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest, 26 (Suppl. 3 287S 310S.
5. Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM (2005) Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. International Journal of Cardiology, 99, 37 45.
6. Lip GYH, Li-Saw-Hee FL (2000) Anticoagulation of older patients. Age and Ageing, 29, 3 4.
7. Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJM, Vandenbroucke JP, Briet E (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. New England Journal of Medicine, 333, 11 17.
8. Oden A, Fahlen M, Hart RG (2006) Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thrombosis Research, 117, 493.
9. Oake N, Fergusson DA, Forster AJ, Van Walraven C (2007) Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. Canadian Medical Association Journal, 176, 1589 1594.
10. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers G (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Archives of Internal Medicine, 167, 239 245.
11. Van Walraven C, Oake N, Wells PS, Forster AJ (2007) Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromobembolic events in the elderly. Chest, 131, 1508 1515.
12. Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S (2004) Safety of anticoagulation therapy in well-informed older patients. Archives of Internal Medicine, 164, 2044 2050.
13. Samsa GP, Matchar DB (2000) Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. Journal of Thrombosis and Thrombolysis, 9, 283 292.
14. Linkins L-A, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Annals of Internal Medicine, 139, 893 900.
15. Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PA (1984) Flexible induction dose regimen for warfarin and prediction of maintenance dose. British Medical Journal, 288, 1268 1270.
16. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Annals of Internal Medicine, 126, 133 136.
17. Crowther MA, Ginsberg JB, Kearon C, Harrison L, Johnson J, Massicotte MP, Hirsh JA (1999) Randomized trial comparing 5-mg and 10-mg warfarin loading doses. Archives of Internal Medicine, 159, 46 48.
18. Kovacs MJ, Rodger M, Anderson DR et al. (2003) Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism: a randomized, double-blind, controlled trial. Annals of Internal Medicine, 138, 714 719.
19. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM (2005) Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest, 127, 2049 2056.
20. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126 (Suppl. 3 204S 233S.
21. Caldwell MD, Berg RL, Zhang KQ et al. (2007) Evaluation of genetic factors for warfarin dose prediction. Clinical Medicine & Research, 5, 8 16.
22. Gage BF (2006) Pharmacogenetics-based coumarin therapy. Hematology, 2006, 467 473.
23. Millican EA, Lenzini PA, Milligan PE et al. (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood, 110, 1511 1515.
24. Aquilante CL, Langaee TY, Lopez LM et al. (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements[ast]. Clinical Pharmacology and Therapeutics, 79, 291 302.
25. Caraco Y, Blotnick S, Muszkat M (2007) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clinical Pharmacology and Therapeutics, 83, 460 470.
26. Anderson JL, Horne BD, Stevens SM et al. (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation, 116, 2563 2570. CIRCULATIONAHA.107.737312.
27. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thrombosis and Haemostasis, 91, 87 94.
28. Sconce EA, Khan TI, Wynne HA et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106, 2329 2333.
29. D'Andrea G, D'Ambrosio RL, Di Perna P et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 105, 645 649.
30. Loebstein R, Dvoskin I, Halkin H et al. (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood, 109, 2477 2480.
31. McWilliam A, Lutter R, Nardinelli C (2008) Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Personalized Medicine, 5, 279 284.
32. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW (2003) The incidence and severity of adverse events affecting patients after discharge from the hospital. Annals of Internal Medicine, 138, 161 167.
33. Garwood CL, Dumo P, Baringhaus S, Laban KM (2008) Quality of anticoagulation care in patients discharged from pharmacist-managed anticoagulation clinic after starting warfarin therapy. Pharmacotherapy, 28, 20 26.
34. Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG (2007) Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. British Journal of Haematology, 136, 26 29.
35. Kimmel SE, Chen Z, Price M et al. (2007) The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Archives of Internal Medicine, 167, 229 235.
36. Arnsten JH, Gelfand JM, Singer DE (1997) Determinants of compliance with anticoagulation: a case-control study. American Journal of Medicine, 103, 11 17.
37. Tang EOYL, Lai CSM, Lee KKC, Wong RSM, Cheng G, Chan TYK (2003) Relationship between patients' warfarin knowledge and anticoagulation control. Annals of Pharmacotherapy, 37, 34 39.
38. Gadisseur APA, Kaptein AA, Breukink-Engbers WGM, Van Der Meer FJM, Rosendaal FR (2004) Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. Journal of Thrombosis and Haemostasis, 2, 584 591.
39. Khan TI, Kamali F, Kesteven P, Avery P, Wynne H (2004) The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. British Journal of Haematology, 126, 557 564.
40. Piso B, Jimenz-Boj E, Krinninger B, Watzke HH (2002) The quality of oral anticoagulation before, during and after a period of patient self-management. Thrombosis Research, 106, 101 104.
41. Erban S (1999) Initiation of warfarin therapy: recommendations and clinical pearls. Journal of Thrombosis and Thrombolysis, 7, 145.
42. Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Archives of Internal Medicine, 158, 1641 1647.
43. Lesho EP, Michaud E, Asquith D (2000) Do anticoagulation clinics treat patients more effectively than physicians? Archives of Internal Medicine, 160, 243 244.
44. Ansell JE, Weitz JI, Comerota AJ (2000) Advances in therapy and the management of antithrombotic drugs for venous thromboembolism. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 266 284.
45. Matchar DB (2003) Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. Cardiac Electrophysiology Review, 7, 379 381.
46. Fitzmaurice DA, Hobbs FDR, Murray ET, Bradley CP, Holder R (1996) Evaluation of computerized decision support for oral anticoagulation management based in primary care. The British Jorunal of General Practice, 46, 533 535.
47. Chatellier G, Colombet I, Degoulet P (1998) An overview of the effect of computer-assisted management of anticoagulant therapy on the quality of anticoagulation. International Journal of Medical Informatics, 49, 311 320.
48. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG (2001) Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica, 86, 1060 1070.
49. Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A, Jespersen J (1998) Multicentre randomised study of computerised anticoagulant dosage. Lancet, 352, 1505 1509.
50. Fitzmaurice DA, Hobbs FD, Delaney BC, Wilson S, McManus R (1998) Review of computerized decision support systems for oral anticoagulant management. British Journal of Haematology, 102, 907 909.
51. Palareti G, Leali N, Coccheri S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet, 348, 423 428.
52. Horstkotte D, Piper C, Wiemer M (1998) Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. Journal of Thrombosis and Thrombolysis, 5, 19 24.
53. Sawicki PT (1999) A structured teaching and self-management program for patients receiving oral anticoagulation a randomized controlled trial. The Journal of the American Medical Association, 281, 145 150.
54. Gardiner C, Williams K, Longair I, Mackie IJ, Machin SJ, Cohen H (2006) A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing. British Journal of Haematology, 132, 598 603.
55. Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FDR (2002) A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. Journal of Clinical Pathology, 55, 845 849.
56. Ansell JE (1999) Empowering patients to monitor and manage oral anticoagulation therapy. The Journal of the American Medical Association, 281, 182 183.
57. Kulinna W, Ney D, Wenzel T, Heene DL, Harenberg J (1999) The effect of self-monitoring the INR on quality of anticoagulation and quality of life. Seminars in Thrombosis and Hemostasis, 25, 123 126.
58. Voller H, Taborski U, Dovifat C et al. (2007) ProTime self-management yielding improvement of fluency and quality of life. Thrombosis and Haemostasis, 98, 889 895.
59. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P (2006) Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. The Lancet, 367, 404 411.
60. Watzke HH, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B (2000) A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thrombosis and Haemostasis, 83, 661 665.
61. Cromheecke ME, Levi M, Colly LP et al. (2000) Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. The Lancet, 356, 97 102.
62. Menendez-Jandula B, Souto JC, Oliver A et al. (2005) Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Annals of Internal Medicine, 142, 1 10.
63. Fitzmaurice DA, Murray ET, McCahon D et al. (2005) Self management of oral anticoagulation: randomised trial. British Medical Journal, 331, 1057.
64. McCahon D, Murray ET, Jowett S et al. (2007) Patient self management of oral anticoagulation in routine care in the UK. Journal of Clinical Pathology, 60, 1263 1267.
65. Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA (2006) Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. Canadian Medical Association Journal, 174, 1847 1852.
66. Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ (2006) Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest, 129, 1155 1166.
67. O'Shea SI, Arcasoy MO, Samsa G, Cummings SE, Thames EH, Surwit RS, Ortel TL (2007) Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. Journal of Thrombosis and Thrombolysis. DOI :.
68. Fitzmaurice DA, Gardiner C (2005) An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. British Journal of Haematology, 131, 156 165.
69. Rose P (1996) Audit of anticoagulant therapy. Journal of Clinical Pathology, 49, 5 9.